VESIcare helps OAE Important Safety Information VESIcare tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The recommended dose of VESIcare is 5 mg once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg once daily. As with other anticholinergic agents, VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. As with other anticholinergic agents, VESIcare should be administered with caution to patients with bladder outflow obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or reduced renal 01 hepatic function. Doses of VESIcare higher than 5 mg are not recommended in patients with severe renal impairment, moderate hepatic impairment, or wher administrated with ketoconazole or other CYP3A4 inhibitors. Use of VESIcare in patients with severe hepatic impairment is not recommended. In placebo-controlled studies, the most common adverse events reported by patients were dry mou (10.9%, 27.6%, 4.2%), constipation (5.4%, 13.4%, 2.9%), blurred vision (3.8%, 4.8%, 1.8%), and dyspepj (1.4%, 3.9%, 1.0%) with VESIcare 5 mg, 10 mg, an placebo, respectively. AGENCY: AbelsonTaylor CREATIVE TEAM: Stephen Neale, Jody Van Swearingen, Barry Levine, Mike Fine, Andy Manilow, Chris Belford, Therese Maginot, Greg Niemczyk, Meredith Weber CLIENT: Astellas
RkJQdWJsaXNoZXIy NDMwNDAx